- Trials with a EudraCT protocol (45)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
45 result(s) found for: Gonadotropin deficiency.
Displaying page 1 of 3.
EudraCT Number: 2015-000512-18 | Sponsor Protocol Number: AGLU09411/EFC12720 | Start Date*: 2015-03-02 | |||||||||||
Sponsor Name:Genzyme Corporation Inc | |||||||||||||
Full Title: A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale | |||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003321-28 | Sponsor Protocol Number: LTS13769 | Start Date*: 2014-05-12 | ||||||||||||||||
Sponsor Name:Genzyme Corporation | ||||||||||||||||||
Full Title: An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of Avalglucosidase Alfa (NeoGAA, GZ402666) In Patients With Pom... | ||||||||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) NL (Completed) DK (Completed) DE (Completed) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002736-13 | Sponsor Protocol Number: TV1106-IMM-30022 | Start Date*: 2015-08-19 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A phase 3, multicenter, randomized, open-label, comparator-controlled study to assess safety and tolerability of weekly TV-1106 compared to daily rhGH (Genotropin®) in adults with growth hormone-de... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Completed) SE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) ES (Prematurely Ended) SI (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) HR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000942-77 | Sponsor Protocol Number: EFC14028 | Start Date*: 2016-07-15 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase ... | |||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) SE (Prematurely Ended) NL (Completed) ES (Completed) CZ (Completed) DE (Completed) BE (Completed) AT (Completed) PL (Completed) IT (Completed) PT (Completed) BG (Completed) HU (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003644-31 | Sponsor Protocol Number: AGLU03206 | Start Date*: 2007-01-18 |
Sponsor Name:Genzyme Europe BV | ||
Full Title: An Open-Label Extension Study of Patients with Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704 | ||
Medical condition: Glycogen Storage Disease type II (Pompe's disease) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) NL (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022231-11 | Sponsor Protocol Number: AGLU07710 | Start Date*: 2012-12-13 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients Aged 8 Years of Age and Older | |||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004005-81 | Sponsor Protocol Number: GC1801 | Start Date*: 2021-01-25 | |||||||||||
Sponsor Name:Instituto Grifols, S.A. | |||||||||||||
Full Title: A prospective, multicenter, open-label, single-arm study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemi... | |||||||||||||
Medical condition: Congenital Afibrinogenaemia and Severe Hypofibrinogenemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004383-62 | Sponsor Protocol Number: GreenGene™F_E_P3 | Start Date*: 2013-12-23 | |||||||||||
Sponsor Name:Green Cross Corporation | |||||||||||||
Full Title: An open label Safety and Efficacy extension study of GreenGene™ F in Previously Treated Patients Diagnosed with Severe Hemophilia A | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002759-42 | Sponsor Protocol Number: AGLU02704 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Myozyme, Recombinant Human Acid alpha-Glucosidase (rhGAA), Treatmen... | |||||||||||||
Medical condition: Glycogen Storage Disease type II (Pompe's disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003475-21 | Sponsor Protocol Number: ACT14132 | Start Date*: 2017-05-17 | ||||||||||||||||
Sponsor Name:Genzyme Corporation | ||||||||||||||||||
Full Title: An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of Avalglucosidase Alfa (NeoGAA, GZ402666) in Patients with Infantile-onset Pompe Disease ... | ||||||||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017737-21 | Sponsor Protocol Number: IDNA 2009-01 | Start Date*: 2011-01-18 | |||||||||||
Sponsor Name:Vifor Pharma | |||||||||||||
Full Title: A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficie... | |||||||||||||
Medical condition: Treatment of iron deficient non anaemic women with ferric carboxymaltose. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001258-25 | Sponsor Protocol Number: MK8962-031-00 | Start Date*: 2012-11-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing... | |||||||||||||
Medical condition: Hypogonadotropic hypogonadism (HH) in males may result from either absent or inadequate gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus or failure of pituitary gonadotropin secr... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000642-21 | Sponsor Protocol Number: ASB-03-06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Multicenter, Multinational, Open-Label Extension Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients with Mucopolysaccharidosis VI | |||||||||||||
Medical condition: Mucopolysaccharidosis Type VI (MPS VI; Maroteaux-Lamy Syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005760-42 | Sponsor Protocol Number: MBGS205 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:Mereo BioPharma 2 Limited | |||||||||||||
Full Title: A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism | |||||||||||||
Medical condition: Hypogonadotropic hypogonadism (HH) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002590-26 | Sponsor Protocol Number: PTA17333 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: A French multicenter Phase 4 open label extension study of long term safety and efficacy in patients with Pompe disease who previously participated in avalglucosidase development studies in France | |||||||||||||
Medical condition: Glycogen storage disease type II | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002155-25 | Sponsor Protocol Number: TAK-448-2001 | Start Date*: 2014-11-17 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism | |||||||||||||
Medical condition: Hypogonadotropic Hypogonadism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004729-42 | Sponsor Protocol Number: 22102014 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Odense University Hospital, department M [...] | |||||||||||||
Full Title: The effect of testosterone replacement in patients with hypogonadotroph hypogonadism due to opioid treatment for non-malignant disease A double-blinded, randomized and placebo-controlled trial | |||||||||||||
Medical condition: Male Hypogonadism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002304-33 | Sponsor Protocol Number: no sponsor | Start Date*: 2006-09-12 | |||||||||||
Sponsor Name:Rijnstate Hospital | |||||||||||||
Full Title: Letrozole Treatment to Normalize Serum Testosterone in Men with Hypogonadotropic Hypogonadism due to Pituitary Damage. | |||||||||||||
Medical condition: Hypogonadotropic hypogonadism in men with pituitary damage other than irradiation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019374-32 | Sponsor Protocol Number: CP-4-003 | Start Date*: 2010-07-15 | |||||||||||
Sponsor Name:ModigeneTech Ltd. | |||||||||||||
Full Title: A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA) | |||||||||||||
Medical condition: Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) SI (Completed) CZ (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003459-39 | Sponsor Protocol Number: AG348-C-011 | Start Date*: 2019-04-10 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects with Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies | |||||||||||||
Medical condition: Pyruvate Kinase Deficiency Haemolytic anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Completed) IE (Completed) NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
